Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28298133 | 0.83 | TAAR1 (0.39) | TAAR1CHRM3NPC1RAB9A | |
| SCHEMBL19277014 | 0.80 | CHRM3 (0.37) | TAAR1CHRM3NPC1RAB9A | |
| SCHEMBL22978805 | 0.78 | CHRM3 (0.36) | TAAR1CHRM3NPC1RAB9A | |
| SCHEMBL20988831 | 0.77 | DRD2 (0.35) | CHRM3NPC1RAB9A | |
| SCHEMBL1492956 | 0.77 | — | — | |
| SCHEMBL31375667 | 0.76 | TAAR1 (0.34) | TAAR1CHRM3NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL31375677 | 0.75 | TAAR1 (0.33) | TAAR1CHRM3NPC1RAB9A | |
| SCHEMBL7569836 | 0.74 | CHRM3 (0.36) | TAAR1CHRM3NPC1RAB9A | |
| SCHEMBL73301 | 0.74 | — | — | |
| SCHEMBL28311208 | 0.74 | NPC1 (0.35) | TAAR1CHRM3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225223-B1 | ORGANIC COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2017-01-11 | — | — | EP | disclosed |
| EP-2225227-B1 | 1',3'-Dihydrospiro[imidazolidin-4,2'-inden]-2,5-diones and 1,3-dihydrospiro[inden-2,3']-pyrroles as CGRP antagonists | BOEHRINGER INGELHEIM INT (DE) | 2015-08-26 | — | — | EP | disclosed |
| US-8829006-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-09 | — | — | US | disclosed |
| US-8466143-B2 | Azepine derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8110575-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| US-20110195954-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-11 | — | — | US | disclosed |
| US-20110021500-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2251339-A2 | COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2251338-A2 | Organic compounds | Boehringer Ingelheim International GmbH (DE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2225223-A2 | ORGANIC COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009065919-A2 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009065920-A2 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | WO | disclosed |
| US-20070015746-A1 | Azepine derivaties as pharmaceutical agents | X-CEPTOR THERAPEUTICS INC. (US) | 2007-01-18 | — | — | US | disclosed |
| EP-1648408-A4 | AZEPINE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2006-11-29 | — | — | EP | disclosed |
| CN-1852748-A | Azepine derivatives as pharmaceutical agents | EXELIXIS INC (US) | 2006-10-25 | — | — | CN | disclosed |
| EP-1648408-A1 | AZEPINE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005009387-A2 | AZEPINE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-CEPTOR THERAPEUTICS INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| EP-1226146-A2 | QUINOLINE AND NAPHTHYRIDINE CARBOXYLIC ACID ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020049223-A1 | Quinoline and naphthyridine carboxylic acid antibacterials | ABBOTT LABORATORIES | 2002-04-25 | — | — | US | disclosed |
| WO-2001032655-A2 | QUINOLINE AND NAPHTHYRIDINE CARBOXYLIC ACID ANTIBACTERIALS | ABBOTT LABORATORIES (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021500-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, CALCA | TAAR1 166/4885CHRM3 141/4885NPC1 1476/4885 |
| US-20020049223-A1 | Quinoline and naphthyridine carboxylic acid antibacterials | NQO2, NQO1, NDUFA7 | TAAR1 2464/4885CHRM3 3353/4885NPC1 215/4885 |
| US-20070015746-A1 | Azepine derivaties as pharmaceutical agents | HTR5A, TACR2, TACR1 | TAAR1 136/4885CHRM3 44/4885NPC1 647/4885 |
| US-20110195954-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, CALCA | TAAR1 160/4885CHRM3 146/4885NPC1 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.